Back door modulation of the farnesoid X receptor: Design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives

Journal of Medicinal Chemistry

Volumn 49, Issue 14, 2006, Pages 4208-4215

  Pellicciari, Roberto ^a   Gioiello, Antimo ^a   Costantino, Gabriele ^a   Sadeghpour, Bahman M ^a   Rizzo, Giovanni ^a   Meyer, Udo ^a   Parks, Derek J ^b   Entrena Guadix, Antonio ^c   Fiorucci, Stefano ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

23 N (CARBO 2' ADAMANTYLOXY) 3ALPHA,7ALPHA DIHYDROXY 24 NOR 5BETA CHOLAN 23 AMINE; 23 N (CARBO 4 CARBOXYBENZYLOXY) 3ALPHA,7ALPHA DIHYDROXY 24 NOR 5BETA CHOLAN 23 AMINE; 23 N (CARBO 4 METHOXYBENZYLOXY) 3ALPHA,7ALPHA DIHYDROXY 24 NOR 5BETA CHOLAN 23 AMINE; 23 N (CARBOBENZYLOXY) 3ALPHA,7ALPHA DIHYDROXY 24 NOR 5BETA CHOLAN 23 AMINE; 23 N (CARBOCINNAMYLOXY) 3ALPHA,7ALPHA DIHYDROXY 24 NOR 5BETA CHOLAN 23 AMINE; 23 N (CARBOISOPROPYLOXY) 3ALPHA,7ALPHA DIHYDROXY 24 NOR 5BETA CHOLAN 23 AMINE; 23 N (CARBOTHIOPHENE 2' METHYLOXY) 3ALPHA,7ALPHA DIHYDROXY 24 NOR 5BETA CHOLAN 23 AMINE; 23 N (CARBOXYCYCLOHEXYLOXY) 3ALPHA,7ALPHA DIHYDROXY 24 NOR 5BETA CHOLAN 23 AMINE; 3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; 3ALPHA,7ALPHA DIFORMYLOXY 5BETA CHOLAN 24 OIC ACID; 6ALPHA ETHYL CHENODEOXYCHOLIC ACID; BILE ACID; CARBOXYL GROUP; CHENODEOXYCHOLIC ACID DERIVATIVE; FARNESOID X RECEPTOR; FARNESOID X RECEPTOR AGONIST; FEXARAMINE; INT 747; LUCIFERASE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; FLUORESCENCE RESONANCE ENERGY TRANSFER; RECEPTOR INTRINSIC ACTIVITY; TRANSACTIVATION;

CELL LINE, TUMOR; CHENODEOXYCHOLIC ACID; DNA-BINDING PROTEINS; DRUG DESIGN; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENES, REPORTER; HISTONE ACETYLTRANSFERASES; HUMANS; LIGANDS; LUCIFERASES; MODELS, MOLECULAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; RESPONSE ELEMENTS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 33745852636     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060294k     Document Type: Article

References (33)

1. Pellicciari, R.; Costantino, G.; Fiorucci, S. Farnesoid X receptor: from structure to potential clinical applications J. Med. Chem. 2005, 48, 5383-5403.
2. Wang, H.; Chen, J.; Hollister, K.; Sowers, L. C.; Forman, B. M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 1999, 3, 543-553.
3. Parks, D. J.; Blanchard, S. G.; Bledsoe, R. K.; Chandra, G.; Consler, T. G.; Kliewer, S. A.; Stimmel, J. B.; Willson, T. M.; Zavacki, A. M.; Moore, D. D.; Lehmann, J. M. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999, 284, 1365-1368.
4. Makishima, M.; Okamoto, A. Y.; Repa, J. J.; Tu, H.; Learned, R. M.; Luk, A.; Hull, M. V.; Lustig, K. D.; Mangelsdorf, D. J.; Shan, B. Identification of a nuclear receptor for bile acids. Science 1999, 284, 1362-1365.
5. Pellicciari, R.; Fiorucci, S.; Camaioni, E.; Clerici, C.; Costantino, G.; Maloney, P. R.; Morelli, A.; Parks, D. J.; Willson, T. M. 6-α-Ethyl- chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 2002, 45, 3569-3572.
6. Maloney, P. R.; Parks, D. J.; Haffner, C. D.; Fivush, A. M.; Chandra, G.; Plunket, K. D.; Creech, K. L.; Moore, L. B.; Wilson, J. G.; Lewis, M. C.; Jones, S. A.; Willson, T. M. Identification of a chemical tool for the orphan nuclear receptor FXR. J. Med. Chem. 2000, 43, 2971-2974.
7. Nicolaou, K. C.; Evans, R. M.; Roecker, A. J.; Hughes, R.; Downes, M.; Pfefferkorn, J. A. Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries. Org. Biomol. Chem. 2003, 1, 908-920.
8. Goodwin, B.; Jones, S. A.; Price, R. R.; Watson, M. A.; McKee, D. D.; Moore, L. B.; Galardi, C.; Wilson, J. G.; Lewis, M. C.; Roth, M. E.; Maloney, P. R.; Willson, T. M.; Kliewer, S. A. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 2000, 6, 517-526.
9. Lu, T. T.; Makishima, M.; Repa, J. J.; Schoonjans, K.; Kerr, T. A.; Auwerx, J.; Mangelsdorf, D. J. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 2000, 6, 507-515.
10. Denson, L. A.; Sturm, E.; Echaverria, W.; Zimmerman, T. L.; Makishima, M.; Mangelsdorf, D. J.; Karpen, S. J. The orphan nuclear receptor shp mediates bile acid-induced inhibition of the rat bile acid transporter ntcp. Gastroenterology 2001, 121, 140-147.
11. Sinal, C. J.; Tohkin, M.; Miyata, M.; Ward, J. M.; Lambert, G.; Gonzales, F. J. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000, 102, 731-744.
12. Duran-Sandoval, D.; Mautino, G.; Martin, G.; Percevault, F.; Barbier, O.; Fruchart, J. C.; Kuipers, F.; Staels, B. Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 2004, 53, 890-898.
13. Stayrook, K. R.; Bramlett, K. S.; Savkur, R. S.; Ficorilli, J.; Todd, C.; Christe, M. E.; Michael, L. F.; Burris, T. P. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 2005, 146, 984-991.
14. Duran-Sandoval, D.; Cariou, B.; Fruchart, J.-C.; Staels, B. Potential regulatory role of the farnesoid X receptor in the metabolic syndrome. Biochimie 2005, 87, 93-98.
15. Wurtz, J. M.; Bourguet, W.; Renaud, J. P.; Vivat, V.; Chambon, P.; Moras, D.; Gronemeyer, H. A canonical structure for the ligand-binding domain of nuclear receptors. Nat. Struct. Biol. 1996, 3, 87-94.
16. Mi, L. Z.; Devarakonda, S.; Harp, J. M.; Han, Q.; Pellicciari, R.; Willson, T. M.; Khorasanizadeh, S.; Rastinejad, F. Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol. Cell 2003, 11, 1093-1100.
17. (a) Bledsoe, R. K.; Montana, V. G.; Stanley, T. B.; Delves, C. J.; Apolito, C. J.; McKee, D. D.; Consler, T. G.; Parks, D. J.; Stewart, E. L.; Willson, T. M.; Williams, S. P. A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor. Cell 2002, 110, 93-105.
18. (b) Brzozowski, A. M.; Pike, A. C.; Dauter, Z.; Hubbard, R. E.; Bonn, T.; Engstrom, O.; Ohman, L.; Greene, G. L.; Gustafsson, J. A.; Carlquist, M. Molecular basis of agonism and antagonism in estrogen receptor. Nature 1997, 389, 753-758.
19. Sack, J. S.; Kish, K. F.; Wang, C.; Attar, R. M.; Kiefer, S. E.; An, Y.; Wu, G. Y.; Scheffler, J. E.; Salvati, M. E.; Krystek, S. R.; et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 4904-4909.
20. Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P. J.; Agard, D. A.; Greene, G. L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998, 95, 927-937.
21. (e) Williams, S. P.; Sigler, P. B. Atomic structure of progesterone complexed with its receptor. Nature 1998, 393, 392-396.
22. Meyer, U.; Costantino, G.; Macchiarulo, A.; Pellicciari, R. Is antagonism of E/Z-guggulsterone at the farnesoid X receptor mediated by a noncanonical binding site? A molecular modeling study. J. Med. Chem. 2005, 48, 6948-6955.
23. Pellicciari, R.; Costantino, G.; Camaioni, E.; Sadeghpour, B. M.; Entrena, A.; Willson, T. M.; Fiorucci, S.; Clerici, C.; Gioiello, A. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. J. Med. Chem. 2004, 47, 4559-4569.
24. Coleman, J. P.; Kirby, L. C.; Setchell, K. D.; Hylemon, P. B.; Pandak, M.; Heuman, D. M.; Vlahcevic, Z. R. Metabolic fate and hepatocyte toxicity of reverse amide analogs of conjugated ursodeoxycholate in the rat. J. Steroid Biochem. Mol. Biol. 1998, 64, 91-101.
25. Goto, J.; Kato, H.; Hasegawa, F.; Nambara, T. Synthesis of monosulfates of unconjugated bile acids. Chem. Pharm. Bull. 1979, 27, 1402-1411.
26. Costantino, G.; Entrena-Gaudix, A.; Macchiarlo, A.; Gioiello, A.; Pellicciari, R. Molecular dynamics simulation of the ligand binding domain of farnesoid X receptor. Insight into helix-12 stability and coactivator peptide stabilization in response to agonist binding. J. Med. Chem. 2005, 48, 3251-3259.
27. Olsen, L.; Pettersson, I.; Hemmingsen, L.; Adolph, H. W.; Jorgensen, F. S. Docking and scoring of metallo-beta-lactamases inhibitors. J. Comput.-Aided Mol. Des. 2004, 18, 287-302
28. Sybyl Molecular Modeling Software; Tripos Inc. (1699 S. Hanley Rd, St. Louis, MO 63144-2913); http://www.tripos.com.
29. (a) Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativity. A rapid access to atomic charges. Tetrahedron, 1980, 36, 3219-3228.
30. (b) Marsili, M.; Gasteiger, J. Charge distributions from molecular topology and pi-orbital electronegativity. Croat. Chem. Acta 1980, 53, 601-614.
31. Gasteiger, J.; Marsili, M. Prediction of proton magnetic resonance shifts: the dependence on hydrogen charges obtained by iterative partial equalization of orbital electronegativity. Org. Magn. Reson. 1981, 15, 353-360.
32. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
33. AutoDock Tools (ADT) program is available from the Molecular Graphics Laboratory, at The Scripps Research Institute; http://www.scripps.edu/inb/olson/ index.html.